Standard BioTools FY2023 revenue $106M (+9%); Q4 gross margin 59.6%; SomaLogic merger closed

STANDARD BIOTOOLS INC.

2023-FY EPS reported -$0.94 revenue$106,340,000

FY2023 revenue $106.3M (+9% YoY); Q4 revenue $28.2M (+4%); instrument sales +46% for FY.
Non-GAAP gross margin 60.1% for FY2023 (+900 bps YoY); net loss $74.7M.
Non-GAAP adjusted EBITDA loss improved $34M to $34.7M; operating cash use down 53%.
Combined pro forma 2023 revenue ~$192M; pro forma cash $565M (incl. SomaLogic's $449.8M).
Merger with SomaLogic closed Jan 5, 2024; integration underway; CEO cites disciplined execution.

item 2.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

STANDARD BIOTOOLS INC. reported the fourth quarter and fiscal year ended December 31, 2023 results: revenue $28.2, net income $(19.8).

Period: the fourth quarter and fiscal year ended December 31, 2023
Revenue: $28.2
Net income: $(19.8)
Result: reported results

Exact text from the filing

2023 Fourth Quarter and Full Year Selected Financial Results 2 Quarter Ended Year Ended (Unaudited, in millions, except percentages) December 31, 2023 December 31, 2023 Revenue $ 28.2 $ 106.3 GAAP gross margin 47.4 % 47.4 % Non-GAAP gross margin 59.6 % 60.1 % Operating expenses $ 34.7 $ 127.1 Non-GAAP operating expenses $ 24.3 $ 98.6 Operating loss $ (21.4 ) $

View on SEC.gov

708 earnings releases filed in the last 30 days. Browse all earnings releases →

STANDARD BIOTOOLS INC. filing history →

Source: SEC EDGAR

accession 0000950170-24-022060

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.